Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Reaches New 52-Week High – Here’s Why

Shares of Swedish Orphan Biovitrum (OTCMKTS:BIOVF) hit a new 52-week high during trading on Friday . The company traded as high as $48.00 and last traded at $48.00, with a volume of 100 shares. The stock had previously closed at $48.00.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Danske lowered Swedish Orphan Biovitrum to a “hold” rating in a research note on Thursday, February 19th. Barclays reaffirmed an “overweight” rating on shares of Swedish Orphan Biovitrum in a research note on Tuesday, February 24th. BNP Paribas Exane raised Swedish Orphan Biovitrum to an “outperform” rating in a research note on Tuesday, February 10th. Zacks Research raised Swedish Orphan Biovitrum to a “hold” rating in a research note on Thursday, May 7th. Finally, HC Wainwright assumed coverage on Swedish Orphan Biovitrum in a research note on Wednesday, May 6th. They issued a “buy” rating for the company. Four equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, Swedish Orphan Biovitrum presently has an average rating of “Moderate Buy”.

Swedish Orphan Biovitrum Price Performance

The company has a debt-to-equity ratio of 0.19, a current ratio of 0.70 and a quick ratio of 0.47. The firm has a market cap of $17.09 billion, a PE ratio of 160.00 and a beta of 0.36. The firm has a 50-day simple moving average of $43.89 and a 200 day simple moving average of $39.39.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) last announced its quarterly earnings data on Tuesday, April 28th. The company reported $0.45 EPS for the quarter, beating the consensus estimate of $0.38 by $0.07. The business had revenue of $755.76 million during the quarter, compared to analyst estimates of $749.76 million. Swedish Orphan Biovitrum had a return on equity of 16.66% and a net margin of 3.37%. As a group, equities analysts expect that Swedish Orphan Biovitrum will post 2.22 EPS for the current year.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm‐based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high‐value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi’s strategy centers on building a global specialty care portfolio by in‐licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company’s marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto‐inflammatory conditions.